Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-α immunization: A 30-month follow-up report

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue 1, 1996, Pages 55-67

  Gringeri, A ^a,i   Santagostino, E ^a   Cusini, M ^a   Muca Perja M ^a   Marinoni, A ^a   Mannucci, P M ^a   Burny, A ^b   Criscuolo, M ^c   Lu, W ^d   Andrieru, J M ^d   Mbika, J P ^e   Lachgar, A ^e   Fall, L S ^e   Chams, V ^e   Feldman, M ^f   Hermans, P ^g   Zagury, J F ^e   Bizzini, B ^e   Musicco, M ^h   Zagury, D ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Biosidus SA   (Argentina)

^d Hopital Laennec   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

ⁱ Hemophilia and Thrombosis Center   (Italy)

Author keywords

AIDS clinical trial; Anti IFN immunization; Anticytokine vaccination; HIV 1; Immunotherapy; Interferon

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON ANTIBODY; RECOMBINANT ALPHA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SYMPTOMATOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 1542429111     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199609000-00009     Document Type: Article

References (38)

1. Zagury D, Bernard J, Leonard R, et al. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-3.
2. Clerici M, Shearer GA. Th1 → Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-10.
3. Zagury D, Gagne I, Reveil B, et al. Repairing the T cell defects in AIDS. Lancet 1985;2:449.
4. Fan J, Bass HZ, Fahey JL. Elevatd IFNγ and decreased 1L-2 gene expression are associated with HIV-1 infection. J Immunol 1993;152:5031-7.
5. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-4.
6. Ambrus JL, Poiesz BJ, Littie MA, Stadler I, Dibepard LA, Charda KC. Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, acquired immunodeficiency syndrome, acquired immunodeficiency syndrome-related complex, or Kaposi's sarcoma and in normal individuals. Am J Med 1989;87:405-7.
7. Francis ML, Meltzer MS, Gendelman HE. Interferons in the persistance, pathogenesis and treatment of HIV infection. AIDS Res Hum Retroviruses 1992;2:199-237.
8. Allen JB, Wong HL, Guyre PM, Simon GL, Wahl SM. Association of circulating receptor FcrRIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-β. J Clin Invest 1991;87;1773-9.
9. Kekow J, Wachsman W, McCutchan JA, Cronin M, Carson DA, Lotz M. Transforming growth factor β and non-cytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci USA 1990;87:8321-5.
10. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-4.
11. Hober D, Haque A, Wattre P, Beaucaire G, Mouton Y, Capron A. Production of tumor necrosis factor α (TNFα) and interleukin-1 (IL-1) in patients with AIDS. Clin Exp Immunol 1989;78:329-33.
12. Lahdevirta J, Maury CPJ, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
13. Lepe-Zuniga JL, Mansell PWA, Remwig L. Idiopathic production of interleukin-1 in the acquired immunodeficiency syndrome. J Clin Microbiol 1987;25:1695-700.
14. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987;3:115-24.
15. + T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-75.
16. Zagury D, Bernard J, Halbreich A, et al. One-year follow-up of vaccine therapy in HIV-infected immune deficient individuals: a new strategy. J Acquire Immune Defic Syndr 1992;5:676-81.
17. Carelli C, Halbreich A, Bernard J, et al. Immunogenicity of combined anti-HIV and antiimmunosuppressive vaccine preparations. Biomed Pharmacother 1992;46:149-53.
18. Gringeri A, Santagostino E, Mannucci PM, et al. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization. J Acquir Immune Defic Syndr 1994;7:978-88.
19. Gringeri A, Santagostino E, Mannucci PM, et al. Anti-alpha interferon immunization: safety and immunogenicity in symptomatic HIV positive patients at high risk of disease progression. Cell Mol Biol 1995;41:381-7.
20. Skurkovich S, et al. Immunosuppressive effect of an anti-interferon serum. Nature 1974;247:551-2.
21. Bellanti JA, Skurkovich SV, et al. preliminary clinical trial of anti-alpha IFN in patients with AIDS: a possible approach for immune enhancement. III International Conference on AIDS, Washington, 1987; Abstract book, 1987: MP 18.
22. Taylor-Papadimitriu J. Effects of interferons on cell growth and function. Interferon 1980;2:13-46.
23. Orenstein JM. Ultrastructural markers in AIDS. Lancet 1983;1:284-5.
24. Preble, et al. Role of interferon in AIDS. Ann NY Acad Sci 1984;437:65.
25. Vadhan-Raj S, et al. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res 1986;46: 417-25.
26. Toth FD, Mosborg-Petersen P, Kiss J, et al. Differential replication of human immunodeficiency virus type 1 in CD8- and CD8+ subsets of natural killer cells: relationship to cytokine production pattern. J Virol 1993;67:5879-88.
27. Zagury JF, Bernard J, Achour A, et al. Identification of CD4 and MHC functional peptide sites and their homology with HIV-1 gp120 oligopeptides: role in AIDS pathogenesis. Proc Natl Acad Sci USA 1993;90:7573-7.
28. Capobianchi MR, Ameglio F, Fei PC, et al. Coordinate induction of interferon α and γ by recombinant HIV-1 glycoprotein 120. AIDS Res Hum Retovir 1993;10:437-43.
29. Ross C, Hansen MB, Shyberg T, Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFNα 2b and human IFNγ in healthy blood donors. Clin Exp Immunol 1990;82:57-62.
30. Bizzini B, Achour A. "Kinoids": the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol 1995;41:351-6.
31. Bizzini B. Structure, composition and principles of detoxification of diphteria and tetanus toxin. In: Manclark CD, ed. Proceedings of an Informal Consultation on the WHO Requirements for Diphtheria, Pertussis and Combined Vaccines. Bethesda, MD: Department of Health and Human Services, US Public Health Service, DHHC Public (FDA) 1991;1174:252.
32. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Virol 1981;37:755.
33. Fall LS, Chams V, Le Coq H, et al. Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection. Cell Mol Biol 1995;41:409-16.
34. Lu W, Han DS, Yuan J, Andrieu JM. Multi-target PCR analysis by capillary electrophoresis and laser-induced fluorescence. Nature 1994;368:269-71.
35. Margolick JB, Munoz A. Donnenberg AD, et al., for the Multicenter AIDS Cohort Study. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nature Med 1995; 1:674-80.
36. Zagury JF, Chams V, Lachgar A, et al. Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis? A model for HIV-1-induced immunopathogenesis. Cell Death Differen 1995;2:23-32.
37. + blood dendritic cells are potent producers of IFNα in response to in vitro HIV-1 infection. J Immunol 1994;152: 4649-62.
38. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.